The United States Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market size is reached a valuation of USD xx.x Billion in 2023, with projections to achieve USD xx.x Billion by 2031, demonstrating a compound annual growth rate (CAGR) of xx.x% from 2024 to 2031.
United States Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market By Application
- Age-Related Macular Degeneration (AMD)
- Diabetic Retinopathy (DR)
- Macular Edema
- Retiopathies
- Ocular Neovascularization
The United States Anti-VEGF drugs market is segmented by application into several key areas. Age-Related Macular Degeneration (AMD) remains the largest segment, accounting for a significant portion of the market share. Anti-VEGF therapies such as ranibizumab and aflibercept are extensively used in the treatment of AMD, which is prevalent among the elderly population.
Diabetic Retinopathy (DR) is another critical application segment driving the demand for Anti-VEGF drugs in the US market. With the rising prevalence of diabetes in the country, the incidence of DR has increased, necessitating effective treatment options to manage vision-threatening complications. Macular Edema, a condition often associated with DR and other retinal diseases, also contributes notably to the market, with therapies targeting vascular leakage and swelling in the macula.